We are live on
!
Find out more
Bellevue Group Portfolio holdings
AUM
$4.75B
Turnover
23.84%
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
(-20%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-19.85%
Top 10 Holdings %
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40
Avg Time Held
3.8
years
Top 10 Avg Time Held
2.6
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$203M |
| 2 |
Gilead Sciences
GILD
|
+$156M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$146M |
| 4 |
Amgen
AMGN
|
+$98.7M |
| 5 |
Viridian Therapeutics
VRDN
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$350M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$235M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$225M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 5 |
Amicus Therapeutics
FOLD
|
+$153M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Energy | 0.07% |
| 3 | Technology | 0.06% |
| 4 | Miscellaneous | 0.05% |
| 5 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Vertex Pharmaceuticals
VRTX
$129B
| $304M | 7.25% |
681,908
+788
| +0.1% | +$367K |
2016 Q1
40 quarters
|
|
2
argenx
ARGX
$53.2B
| $229M | 5.44% |
313,000
-148,854
| -32% | -$116M |
2018 Q4
29 quarters
|
|
|
3
Regeneron Pharmaceuticals
REGN
$82B
| $215M | 5.12% |
278,674
+264,746
| +1,901% | +$203M |
2019 Q4
25 quarters
|
|
4
Scholar Rock
SRRK
$4.95B
| $176M | 4.19% |
3,584,573
-472,019
| -12% | -$21.2M |
2019 Q2
27 quarters
|
|
|
5
Gilead Sciences
GILD
$195B
| $163M | 3.88% |
1,169,879
+1,117,127
| +2,118% | +$156M |
2016 Q1
40 quarters
|
|
|
6
Revolution Medicines
RVMD
$40.6B
| $150M | 3.57% |
1,544,456
-3,461,263
| -69% | -$350M |
2020 Q4
21 quarters
|
|
|
7
Ionis Pharmaceuticals
IONS
$7.33B
| $137M | 3.25% |
1,818,665
-2,983,534
| -62% | -$235M |
2016 Q1
40 quarters
|
|
8
Intuitive Surgical
ISRG
$151B
| $132M | 3.14% |
286,654
-35,374
| -11% | -$17.9M |
2016 Q1
40 quarters
|
|
|
9
Viridian Therapeutics
VRDN
$2.22B
| $132M | 3.13% |
6,726,144
+2,367,617
| +54% | +$70.3M |
2025 Q4
1 quarter
|
|
10
Krystal Biotech
KRYS
$9.77B
| $124M | 2.96% |
481,785
+71,462
| +17% | +$19M |
2021 Q4
17 quarters
|
|
|
11
DELISTED
Crinetics Pharmaceuticals
CRNX
| $119M | 2.84% |
3,280,000
+3,275,960
| +81,088% | +$146M |
2025 Q4
1 quarter
|
|
12
Abbott
ABT
$181B
| $118M | 2.81% |
1,151,635
-165,280
| -13% | -$18.7M |
2016 Q1
40 quarters
|
|
13
DELISTED
Nuvalent
NUVL
| $108M | 2.57% |
1,053,268
+15,800
| +2% | +$1.61M |
2025 Q4
1 quarter
|
|
|
14
Amgen
AMGN
$235B
| $104M | 2.47% |
295,358
+276,869
| +1,497% | +$98.7M |
2016 Q1
40 quarters
|
|
15
Boston Scientific
BSX
$64B
| $92M | 2.19% |
1,466,894
-92,712
| -6% | -$7.42M |
2016 Q1
40 quarters
|
|
16
Enliven Therapeutics
ELVN
$2.88B
| $91M | 2.17% |
+2,320,867
| New | +$64.3M |
2026 Q1
0 quarters
|
|
17
Immunocore
IMCR
$1.52B
| $84.3M | 2.01% |
2,796,803
| – | – |
2023 Q3
10 quarters
|
|
18
Medtronic
MDT
$122B
| $83M | 1.97% |
957,329
+190,737
| +25% | +$18.3M |
2016 Q1
40 quarters
|
|
19
Alnylam Pharmaceuticals
ALNY
$31.3B
| $77.6M | 1.85% |
234,543
-211,360
| -47% | -$71.9M |
2016 Q1
40 quarters
|
|
20
Relay Therapeutics
RLAY
$3.79B
| $77.6M | 1.85% |
7,795,242
-550,122
| -7% | -$4.92M |
2020 Q3
22 quarters
|
|
21
Stryker
SYK
$112B
| $71.4M | 1.7% |
217,237
-143,340
| -40% | -$51.5M |
2016 Q1
40 quarters
|
|
22
Vaxcyte
PCVX
$10.3B
| $69.2M | 1.65% |
+1,190,697
| New | +$64.6M |
2026 Q1
0 quarters
|
|
23
Vera Therapeutics
VERA
$2.06B
| $68.8M | 1.64% |
1,710,771
+12,619
| +0.7% | +$544K |
2025 Q4
1 quarter
|
|
24
Edwards Lifesciences
EW
$50.8B
| $67.2M | 1.6% |
839,451
-203,645
| -20% | -$16.8M |
2016 Q1
40 quarters
|
|
|
DMRA
25
Damora Therapeutics
DMRA
$1.16B
| $59.5M | 1.42% |
+2,298,000
| New | +$59.1M |
2026 Q1
0 quarters
|
|
Similar funds
PTC
Bellevue Group's Q1 2026 Portfolio in Review
As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.
Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.
- Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
- Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
- Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
- Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
- Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
- Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.